Article
Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial.
The Lancet. Oncology - 1 Apr 2017
Schreuer Max, Jansen Yanina, Planken Simon, Chevolet Ines, Seremet Teofila, Kruse Vibeke, Neyns Bart
Abstract excerpt
BACKGROUND: Patients with BRAFV600-mutant melanoma benefit from treatment with the combination of BRAF and MEK inhibitors, but resistance and disease progression develops in most patients. Preclinical studies and case studies have indicated that acquired resistance to BRAF inhibition can be reversible. We aimed to assess the anti-tumour activity of rechallenge with BRAF plus MEK inhibition in a prospective...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.